Results 91 to 100 of about 8,510 (199)

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden [PDF]

, 2019
Introduction The highly selective ALK receptor tyrosine kinase (ALK) inhibitor alectinib is standard therapy for ALK-positive lung cancers; however, some tumors quickly develop resistance.
Higo, Hisao, Hotta, Katsuyuki, Ichihara, Eiki, Kano, Hirohisa, Kayatani, Hiroe, Kiura, Katsuyuki, Kubo, Toshio, Maeda, Yoshinobu, Makimoto, Go, Matsubara, Takehiro, Ninomiya, Kiichiro, Ninomiya, Takashi, Nishii, Kazuya, Ohashi, Kadoaki, Rai, Kammei, Sato, Akiko, Tabata, Masahiro, Takata, Minoru, Tomida, Shuta, Toyooka, Shinichi, Watanabe, Hiromi   +20 more
core   +1 more source

Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study

Pediatric Blood &Cancer, Volume 72, Issue 12, December 2025.
ABSTRACT Background Patients with high‐risk neuroblastoma (HR‐NBL) who experience disease progression (PD) during first‐line treatment prior to high‐dose chemotherapy (HDC) represent a rare and understudied subgroup, for whom treatment strategies are poorly defined and prognosis appears to be extremely poor.
Claudia Pasqualini, Stéphanie Proust, Gudrun Schleiermacher, Marion Gambart, Sarah Jannier, Arnaud Petit, Chrystelle Dupraz, Estelle Thebaud, Yves Reguerre, Lee Aymar Ndounga‐Diakou, Salim Laghouat, Anne Sophie Defachelles, Pablo Berlanga   +12 more
wiley   +1 more source

KANK1‐ALK, a rare ALK fusion in mucinous lung adenocarcinoma with primary resistance to ALK‐TKI treatment: A case report

Precision Medical Sciences, Volume 14, Issue 4, Page 156-159, December 2025.
Abstract Patients harboring rearrangements of anaplastic lymphoma kinase (ALK) fusion may respond differently to ALK tyrosine kinase inhibitors (TKIs) depending on changes in the type of ALK rearrangements. We report the first documented case of KANK1‐ALK fusion in mucinous lung adenocarcinoma, co‐occurring with TP53 mutation.
Leilei Zhou, Wei Huang, Yaning Zhu, Jipeng Wang   +3 more
wiley   +1 more source

LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Communications Biology
The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusion.
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi   +19 more
doaj   +1 more source

Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials

Statistics in Medicine, Volume 44, Issue 28-30, December 2025.
ABSTRACT Accurate prediction of key milestone dates, such as the timing of interim and final analyses, is crucial in event‐driven clinical trials with time‐to‐event endpoints. These predictions facilitate timely decision‐making, enhance strategic planning and optimize resource allocation while minimizing patient exposure to potentially ineffective or ...
Jingyan Fu, Dan Zhao, Donia Skanji, Hua Liu, Rui (Sammi) Tang, Ying Yuan   +5 more
wiley   +1 more source

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceResearch in context

EBioMedicine, 2019
Background: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R.
Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +16 more
doaj   +1 more source

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer [PDF]

Consenso; Eventos adversos; Cáncer de pulmón de células no pequeñasConsens; Esdeveniments adversos; Càncer de pulmó de cèl·lules no petitesConsensus; Adverse events; Non-small cell lung cancerThe use of anaplastic lymphoma kinase (ALK) tyrosine kinase ...
Arriola, Edurne, Bernabé, Reyes, Bernardez, Beatriz, Bruna, Jordi, De Castro, Javier, FELIP, ENRIQUETA, Garcia Campelo, Rosario   +6 more
core   +1 more source

Belizatinib is a potent inhibitor for non-small cell lung cancers driven by different variants of EML4-ALK fusion proteins carrying L1196M-mutations [PDF]

, 2022
Structural fusions of EML4 with ALK kinase might lead to signaling abnormalities that drive NSCLC. Although approved specific ALK inhibitors have led to excellent initial responses in ALK positive NSCLC patients, acquired resistance to these inhibitors ...
Li, Pan
core  

The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer [PDF]

, 2020
The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of ...
Bazan V., Galvano A., Gristina V., Iacono F., Mantia M. L., Russo A.   +5 more
core   +1 more source

Salvage Surgery Following Systemic Therapy in Initially Unresectable Non‐Small Cell Lung Cancer

Thoracic Cancer, Volume 16, Issue 24, December 2025.
Salvage pulmonary resection after systemic therapy for initially unresectable non‐small cell lung cancer achieved a high R0 rate with minimal morbidity and no perioperative mortality. Careful multidisciplinary selection facilitated a durable 5‐year survival rate of 75%.
Katsutoshi Seto, Yoshitsugu Horio, Katsuhiro Masago, Eiichi Sasaki, Hiroaki Kuroda, Yuta Matsubayashi, Hisanori Iwashimizu, Osamu Noritake, Keiyu Sato, Takuya Matsui, Soichiro Suzuki, Junichi Shimizu, Yutaka Fujiwara, Noriaki Sakakura   +13 more
wiley   +1 more source